Long-term persistence with antihypertensive drugs in new patients
Open Access
- 1 June 2002
- journal article
- research article
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 16 (6) , 439-444
- https://doi.org/10.1038/sj.jhh.1001418
Abstract
The objective of this study was to investigate stay-on-therapy patterns over 3 years among patients prescribed different classes of antihypertensive drugs for the first time. A retrospective analysis of information recorded in the drugs database of the Local Health Unit of Ravenna (Italy) was carried out on 7312 subjects receiving a first prescription for diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors or angiotensin II antagonists between 1 January and 31 December 1997. Patients were followed up for 3 years. All prescriptions of antihypertensive drugs filled during the follow-up periods were considered. The patients continuing or discontinuing the initial treatment, the duration of treatment, and the doses taken were all calculated, as well as main factors influencing the persistence rate. The drugs prescribed were predominantly ACE-inhibitors, followed by calcium channel blockers, diuretics, beta-blockers and angiotensin II antagonists. A total of 57.9% of patients continued their initial treatment during the 3-year follow-up period, 34.5% discontinued the treatment, whilst 7.6% were restarted on a treatment in the third year. Persistence with treatment was influenced by: age of patient (persistence rate increasing proportionately with advancing years), type of drug first prescribed (persistence rate higher with angiotensin II antagonists, progressively lower with ACE-inhibitors, beta-blockers, calcium channel blockers and diuretics), gender of patient (persistence was better in males), age of general practitioner (GP) (the younger the GP, the better the persistence rate) and gender of GP (better stay-on-therapy rate with male GP prescribing). In the case of patients treated continuously, mean daily dose increased progressively over the 3 years. With adequate markers, helpful data can be collected from prescription claims databases for the purpose of monitoring the persistence of patients in continuing their medication, and the quality of antihypertensive treatment in a general practice setting.Keywords
This publication has 19 references indexed in Scilit:
- Blood pressure screening, management and control in EnglandJournal Of Hypertension, 1998
- The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressureArchives of internal medicine (1960), 1997
- Hypertension awareness, treatment and control in the community: is the ‘rule of halves’ still valid?Journal of Human Hypertension, 1997
- Risk factors for antihypertensive medication refill failure by patients under Medicaid managed careClinical Therapeutics, 1996
- Maintaining long-term control of blood pressure: The role of improved complianceClinical Cardiology, 1995
- Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertensionThe American Journal of Cardiology, 1995
- Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)The Lancet, 1991
- Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research GroupJAMA, 1991
- The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: A review of randomized controlled trialsProgress in Cardiovascular Diseases, 1986
- Clinic attendance in the hypertension detection and follow-up program.Hypertension, 1982